Analyst consensus rating
TransMedics Group Analyst Rating: Buy
TMDX is rated Buy by 10 analysts with a $97.30 target. As of 2026-08-25.
Direct answer
TransMedics Group's consensus rating is Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $97.30.
Forecast evidence checked August 25, 2026.
Get free TransMedics Group email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $93.62
- Average price target
- $97.30
- High price target
- $125.00
- Low price target
- $65.00
- Low target gap
- -30.6%
- Target upside
- +3.9%
- High target gap
- +33.5%
- Target range width
- 64.1%
- Consensus rating
- Buy
- Analysts
- 10
- Evidence date
- August 25, 2026
- Valid through
- September 1, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for TransMedics Group?
TransMedics Group has a verified Buy consensus. The same dataset has an average price target of $97.30.
How far are TransMedics Group's low and high targets from the recorded price?
The low target implies -30.6%, while the high target implies +33.5%.
How many analysts are included in TransMedics Group's consensus?
The verified consensus includes 10 analysts.
How is TransMedics Group's target upside or downside calculated?
The average target of $97.30 is divided by the recorded price of $93.62, then one is subtracted to produce +3.9%. This does not guarantee a future return.
When was TransMedics Group's analyst forecast verified?
The data was verified on 2026-08-25. The dataset is valid through 2026-09-01.